发明授权
US08052970B2 Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
有权
溶酶体磷脂酶A2（LPLA2）活性作为鉴定和治疗系统性红斑狼疮的诊断和治疗靶点
- 专利标题： Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
- 专利标题（中）： 溶酶体磷脂酶A2（LPLA2）活性作为鉴定和治疗系统性红斑狼疮的诊断和治疗靶点
-
申请号： US12495209申请日： 2009-06-30
-
公开(公告)号： US08052970B2公开(公告)日： 2011-11-08
- 发明人: James A. Shayman , Akira Abe , Robert Kelly , Jessica Kollmeyer , Ye Lu
- 申请人： James A. Shayman , Akira Abe , Robert Kelly , Jessica Kollmeyer , Ye Lu
- 申请人地址： US MI Ann Arbor
- 专利权人： The Regents of the University of Michigan
- 当前专利权人： The Regents of the University of Michigan
- 当前专利权人地址： US MI Ann Arbor
- 代理机构： Marshall, Gerstein & Borun LLP
- 主分类号： A61K38/46
- IPC分类号： A61K38/46
摘要：
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
公开/授权文献
信息查询
IPC分类:
